The novel schizophrenia drug showing renewed potential for better outcomes A novel acetylcholine receptor drug has become the first new medicine to treat schizophrenia in decades. But even after gaining approval in the United States, experts are still conflicted on its benefits over current antipsychotic medicines.…
Recognition and management of delirium An overview of delirium, its symptoms and subtypes, including how to assess and diagnose, with an overview of non-pharmacological and pharmacological management.…
Enhancing medicines safety for people with learning disabilities and autism through STOMPHealthcare professionals will be familiar with ‘The Oliver McGowan mandatory training on learning disability and autism’. This training serves as a powerful reminder of the devastating consequences related to inappropriate prescribing and emphasises the need for reform in how we manage medicines…
Around 360,000 patients at risk of being ‘trapped’ on antipsychotics, researchers warn The British Journal of General Practice's cross-sectional study highlights that between 360,000 and 390,000 patients in the UK could be being prescribed long-term antipsychotics "without regular psychiatric review”.…
Government-funded trial will test psilocybin as treatment for opioid use disorder The project is one of four funded by the National Institute for Health and Care Research aimed at cutting harm from illegal drugs.…
Prescribing nature to boost mental health This episode of The PJ Pod looks at the evidence for green social prescribing and how pharmacists can help their patients to connect with nature.…
Prescribing dilemma: balancing risk and benefit when treating sertraline sexual dysfunction The first of a new series of articles exploring real-world dilemmas that pharmacist prescribers encounter in clinical practice.…
Psilocybin may be as effective as escitalopram in treating depression, study suggests A meta-analysis has found similar effectiveness of psilocybin compared with escitalopram in the treatment of depression, but the study does have limitations.…
Schizophrenia: symptoms, diagnosis and treatment How pharmacists can recognise the signs and symptoms of schizophrenia — a psychotic condition that affects more than 685,000 people in the UK — with an overview of treatment options, side effects and management advice.…
Largest ever trial of ketamine to treat alcohol abuse to launch across eight NHS sites The phase III clinical trial will explore the use of low-dose ketamine combined with psychological support as a therapy for people with alcohol use disorder.…
